Published in Neuropsychopharmacology on January 16, 2013
A Multicenter Study of NAP (AL-108) in Schizophrenia (AL-108) | NCT00505765
Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies. Transl Psychiatry (2015) 1.49
Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry (2013) 0.99
The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry (2014) 0.90
Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update. Dialogues Clin Neurosci (2013) 0.90
Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Sci Rep (2015) 0.87
N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients. Sci Rep (2015) 0.83
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy (2014) 0.81
Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory. Mol Psychiatry (2016) 0.78
Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. J Alzheimers Dis (2015) 0.77
ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. Front Aging Neurosci (2015) 0.77
Understanding schizophrenia as a disorder of consciousness: biological correlates and translational implications from quantum theory perspectives. Clin Psychopharmacol Neurosci (2015) 0.77
The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings. Front Endocrinol (Lausanne) (2017) 0.76
ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Mol Psychiatry (2017) 0.75
Relationships between dorsolateral prefrontal cortex metabolic change and cognitive impairment in first-episode neuroleptic-naive schizophrenia patients. Medicine (Baltimore) (2017) 0.75
Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry (2000) 6.91
Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry (2000) 4.84
N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol (2007) 4.63
Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A (2001) 3.45
Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex (2000) 3.37
Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry (1998) 3.26
Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry (1995) 3.21
A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry (1998) 2.24
Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry (1998) 2.19
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology (2005) 1.83
Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J Comp Neurol (1998) 1.83
Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry (2004) 1.61
Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry (2007) 1.58
Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res (2003) 1.38
Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther (2007) 1.30
The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry (2001) 1.22
Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res (2006) 1.22
Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry (1997) 1.20
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am (2009) 1.17
Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain. Radiology (2005) 1.15
Toward quantitative short-echo-time in vivo proton MR spectroscopy without water suppression. Magn Reson Med (2006) 1.13
Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. Biol Psychiatry (2010) 1.11
Structural neuroimaging in schizophrenia: from methods to insights to treatments. Dialogues Clin Neurosci (2010) 0.99
Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology (2006) 0.98
Understanding aberrant white matter development in schizophrenia: an avenue for therapy? Expert Rev Neurother (2011) 0.96
Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci (2005) 0.95
Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am J Psychiatry (2003) 0.92
High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia. Am J Psychiatry (2002) 0.91
The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: relationship with treatment response. Psychiatry Res (2009) 0.91
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat (2012) 0.90
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides (2010) 0.87
A review of 1H MR spectroscopy findings in Alzheimer's disease. Neuroimaging Clin N Am (2005) 0.82
Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides (2010) 0.79
Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biol Psychiatry (1996) 0.79
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Mapping cortical change across the human life span. Nat Neurosci (2003) 8.98
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Detection of functional connectivity using temporal correlations in MR images. Hum Brain Mapp (2002) 7.75
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull (2004) 7.58
Open Access Series of Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults. J Cogn Neurosci (2007) 7.31
Prediction of individual brain maturity using fMRI. Science (2010) 7.29
The maturing architecture of the brain's default network. Proc Natl Acad Sci U S A (2008) 7.28
Development of distinct control networks through segregation and integration. Proc Natl Acad Sci U S A (2007) 6.85
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
The WU-Minn Human Connectome Project: an overview. Neuroimage (2013) 5.49
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci (2008) 5.12
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry (2005) 4.28
Boundary and medial shape analysis of the hippocampus in schizophrenia. Med Image Anal (2004) 4.25
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A (2009) 4.05
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry (2006) 3.28
Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol (2003) 3.26
Sex differences in cortical thickness mapped in 176 healthy individuals between 7 and 87 years of age. Cereb Cortex (2006) 3.23
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
The leading sense: supramodal control of neurophysiological context by attention. Neuron (2009) 3.12
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull (2007) 2.94
Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry (2012) 2.94
Multisensory auditory-visual interactions during early sensory processing in humans: a high-density electrical mapping study. Brain Res Cogn Brain Res (2002) 2.93
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry (2003) 2.83
Resting-state fMRI in the Human Connectome Project. Neuroimage (2013) 2.78
Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. Neuroimage (2003) 2.77
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci U S A (2005) 2.73
Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet (2003) 2.71
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Normal development of brain circuits. Neuropsychopharmacology (2010) 2.64
The circumplex model of affect: an integrative approach to affective neuroscience, cognitive development, and psychopathology. Dev Psychopathol (2005) 2.64
Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med (2006) 2.62
Altered emotional interference processing in affective and cognitive-control brain circuitry in major depression. Biol Psychiatry (2007) 2.61
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull (2009) 2.61
Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. J Neurosci (2007) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry (2002) 2.52
Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI study. Schizophr Res (2009) 2.44
The effects of poverty on childhood brain development: the mediating effect of caregiving and stressful life events. JAMA Pediatr (2013) 2.40
The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry (2013) 2.39
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
A theory of cognitive control, aging cognition, and neuromodulation. Neurosci Biobehav Rev (2002) 2.37
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry (2005) 2.35
Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation (2002) 2.32
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 2.32
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry (2006) 2.31
Do you see what I am saying? Exploring visual enhancement of speech comprehension in noisy environments. Cereb Cortex (2006) 2.29
Intact attentional control of working memory encoding in schizophrenia. J Abnorm Psychol (2006) 2.28
Morphometric assessment of the heteromodal association cortex in schizophrenia. Am J Psychiatry (2004) 2.27
The brief negative symptom scale: psychometric properties. Schizophr Bull (2010) 2.27
Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain (2006) 2.26
Flexible neural mechanisms of cognitive control within human prefrontal cortex. Proc Natl Acad Sci U S A (2009) 2.26